Clinical Trials Directory

Trials / Completed

CompletedNCT05301387

The Effect of Ganglion Sphenopalatine Block (GSP-block) Follow-Up

The Effect of Ganglion Sphenopalatine Block (GSP-block) Versus Placebo on Postdural Puncture Headache: Follow Up

Status
Completed
Phase
Study type
Observational
Enrollment
38 (actual)
Sponsor
University Hospital Bispebjerg and Frederiksberg · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the long term effects of the ganglion sphenopalatine block (GSP block) on postdural puncture headache.

Detailed description

Adult patients with postdural puncture headache was enrolled in main study (NCT03652714). In the main study the patients was randomised to receive a ganglion sphenopalatine block (GSP-block) with either local anesthetic (lidocaine + ropivacaine) or placebo (isotone NaCl). Following inclusion in the main study all participants are sent a follow-up questionnaire. Primary outcome is disability due to headache defined as moderate to severe disability measured with Migraine Disability Assessment Test (MIDAS) in the 3 months following initial block and average pain score in the 3 months following the initial block on a 0-10 pain intensity scale. Secondary outcome is disability due to headache defined as moderate to severe disability measured with Migraine Disability Assessment Test (MIDAS) in the 3 previous months as well as average pain scores in the previous 3 months, days with headache and long and short term side effects of the block.

Conditions

Interventions

TypeNameDescription
PROCEDUREGanglion Sphenopalatine BlockBlock performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL or Block performed with bilaterally inserted q-tips with isotone NaCl

Timeline

Start date
2021-11-26
Primary completion
2022-04-19
Completion
2022-04-19
First posted
2022-03-29
Last updated
2022-04-29

Locations

1 site across 1 country: Denmark

Source: ClinicalTrials.gov record NCT05301387. Inclusion in this directory is not an endorsement.